12/4/2024

Janusmed amning

Janusmed amning – olsalazinnatrium

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Olsalazin

Olsalazin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Mezavant (mesalazin). Produktresumé. Läkemedelsverket. [updated 2019-02-08, cited 2019-04-23]

  2. Jenss H, Weber P, Hartmann F. 5-Aminosalicylic acid and its metabolites in breast milk during lactation. Am J Gastroenterol. 1990;85:331. Letter.

  3. Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet. 1993;342(8871):618-9.

  4. Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand. 1994;73(5):399-402.

  5. Silverman DA, Ford J, Shaw I, Probert CS. Is mesalazine really safe for use in breastfeeding mothers?. Gut. 2005;54(1):170-1.

  6. Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Determination of Mesalamine levels in Human Milk as a Function of Dose. Breastfeed Med. 2019;14(2):98-101.

  7. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 1993; (168): 1393-1399.

  8. Xu Y, Tan B, Ma L, Song Y, Zhou X, Qi Q, et al. Case Report Inflammatory bowel disease in pregnancy: a report of 7 cases and review of the literature. Int J Clin Exp Med. 2017;10(3):5525-5532.

  9. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;1(8634):383.

  10. SPC Dipentum (olsalazin). Atnahs Pharma UK Limited. (citerad 2019-04-17)

  11. Miller LG, Hopkinson JM, Motil KJ, Corboy JE, Andersson S. Disposition of olsalazine and metabolites in breast milk. J Clin Pharmacol. 1993;33(8):703-6.

  1. Mezavant (mesalazin). Produktresumé. Läkemedelsverket. [updated 2019-02-08, cited 2019-04-23]
  2. Jenss H, Weber P, Hartmann F. 5-Aminosalicylic acid and its metabolites in breast milk during lactation. Am J Gastroenterol. 1990;85:331. Letter.
  3. Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet. 1993;342(8871):618-9.
  4. Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand. 1994;73(5):399-402.
  5. Silverman DA, Ford J, Shaw I, Probert CS. Is mesalazine really safe for use in breastfeeding mothers?. Gut. 2005;54(1):170-1.
  6. Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Determination of Mesalamine levels in Human Milk as a Function of Dose. Breastfeed Med. 2019;14(2):98-101.
  7. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 1993; (168): 1393-1399.
  8. Xu Y, Tan B, Ma L, Song Y, Zhou X, Qi Q, et al. Case Report Inflammatory bowel disease in pregnancy: a report of 7 cases and review of the literature. Int J Clin Exp Med. 2017;10(3):5525-5532.
  9. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;1(8634):383.
  10. SPC Dipentum (olsalazin). Atnahs Pharma UK Limited. (citerad 2019-04-17)
  11. Miller LG, Hopkinson JM, Motil KJ, Corboy JE, Andersson S. Disposition of olsalazine and metabolites in breast milk. J Clin Pharmacol. 1993;33(8):703-6.

Innehållet senast uppdaterat 11/7/2024